Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from CK Life Sciences International (Holdings), Inc. ( (HK:0775) ) is now available.
CK Life Sciences International (Holdings), Inc. announced a transaction involving the sale of 100% membership interests in a subsidiary to a purchaser for US$125 million, with additional milestone payments up to US$95 million. The transaction aims to combine the businesses of Polynoma and the purchaser, enhancing their therapeutic pipeline with complementary cancer treatments and leveraging the purchaser’s Nasdaq listing to promote and fundraise for the development of seviprotimut-L, a melanoma vaccine.
The most recent analyst rating on (HK:0775) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on CK Life Sciences International (Holdings), Inc. stock, see the HK:0775 Stock Forecast page.
More about CK Life Sciences International (Holdings), Inc.
CK Life Sciences International (Holdings), Inc. operates in the biotechnology industry, focusing on the development of therapeutic candidates for cancer treatment. The company is involved in creating innovative solutions to address significant unmet needs in oncology, with a market focus on cancer vaccines and treatments for metastatic cancer.
Average Trading Volume: 7,743,813
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.8B
See more data about 0775 stock on TipRanks’ Stock Analysis page.